All Oncology News

Jason M. Long, MD, discusses the latest developments with minimally invasive surgical approaches in the treatment of patients with non–small cell lung cancer (NSCLC).

Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.

M. Patricia Rivera, MD, discusses the potential of lung cancer screening, challenges in its adoption, and methods to enhance its efficacy.

Edward S. Kim, MD, recaps the findings from the PACIFIC study of durvalumab and discussed the treatment of patients with stage III NSCLC.

Reshma Mahtani, DO, discusses the tolerability of CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer.

Veda Giri, MD, discusses the developing role of genetic testing for the screening and management of patients with prostate cancer.

First-line platinum-containing chemotherapy plus the anti-PD-1 agent pembrolizumab, followed by pembrolizumab maintenance, appeared feasible and safe for patients with advanced ovarian cancer, preliminary data from a small clinical trial suggested.

Japanese regulators have granted a Sakigake designation to trastuzumab deruxtecan (DS-8201), for the treatment of patients with HER2-positive gastric cancer that is refractory to trastuzumab (Herceptin).

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

EP2006, a filgrastim biosimilar, produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 phase III breast cancer studies from the United States and Europe.

A rolling new drug application has been completed for larotrectinib (LOXO-101) for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding the option of a 4-week dosing schedule to the label for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC).

The FDA has granted enfortumab vedotin a breakthrough therapy designation for patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy.

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel significantly improved overall survival compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Leonard G. Gomella, MD, shares his insight on this year's expected advances in the field of prostate cancer.

Chad Pecot, MD, discusses the rapidly growing area of combination immunotherapy in non–small cell lung cancer.

Hyman B Muss, MD, a 2017 Giants of Cancer Care® award winner is a pioneer in the treatment of older patients with cancer.

Jeffrey Melson Clarke, MD, discusses the latest developments with biomarkers in NSCLC.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to trastuzumab.

Chloe E. Atreya, MD, PhD, discusses the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

Tiffany A. Traina, MD, discussed the potential for PARP inhibitors, as well as immunotherapy and antibody-drug conjugates, for the treatment of patients with triple-negative breast cancer.

James Luke Godwin, MD, recaps recent advancements in frontline metastatic castration-sensitive prostate cancer and highlights emerging agents with potential in this space.

Japan’s Pharmaceuticals and Medical Devices Agency has approved lenvatinib mesylate for the frontline treatment of patients with unresectable hepatocellular carcinoma.

Rovalpituzumab Tesirine (Rova-T) delivered disappointing preliminary results in the third-line setting for patients with relapsed/refractory small cell lung cancer with high DLL3 expression.

Ponatinib maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML).

The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

The FDA has approved nilotinib for the first- and second-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.

Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.

Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.

Eric A. Collisson, MD, discusses ongoing efforts to advance precision medicine in GI malignancies to improve the standard of care.